2019 Global Pharmaceutical Company TOP10
-
Last Update: 2019-11-20
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On November 18, foreign biotechnology website Gen released the list of "top 10 global pharmaceutical companies in 2019", which is ranked according to the market value as of November 13, 2019 Data shows that the total market value of top 10 pharmaceutical companies in 2019 is US $1792 trillion, down 2.9% from US $1845 trillion in 2018, but up 4% from 2017 This year's list includes all 10 pharmaceutical companies on the list in 2018, five of which are up and five down in market value AstraZeneca (+ 21.3%) gained the most in market value, followed by Merck (+ 11.4%), GlaxoSmithKline (+ 9.0%), Sanofi (+ 1.1%) and Novartis (+ 0.3%) The biggest drop in market value was Pfizer (- 18.9%), followed by Johnson & Johnson (- 10.7%), Lilly (- 8.6%), Aberdeen (- 4.4%), Roche (- 1.6%) This year, Pfizer ranked fifth with just over $205 billion, down three places from the 2018 list Market observers attributed the decline to Pfizer's sales decline in the second and third quarters of this year, even though the sales and profit results in the third quarter actually exceeded expectations, and the company has tried to improve shareholder value through acquisitions, such as the $11.4 billion acquisition of arraybiopharma completed on July 30 Although the market value of Bristol Myers Squibb in 2019 is a double-digit (11.2%) leap from the market value of US $86.311 billion in 2018, it still ranks 11th and misses the top 10 just like last year This is the result of Bristol Myers Squibb's planned $74 billion acquisition of new base Recently, the huge acquisition was approved by the Federal Trade Commission and is expected to be completed on November 20, 2019 In the past three years, Bayer's market value dropped the most, ranking 12th, with a market value of $72.365 billion 17.4% lower than that of $87.64 billion in 2016 In May 2016, Bayer announced plans to acquire Monsanto for us $66 billion The deal was completed in June 2018, with an actual transaction amount of US $63 billion In its third quarter results on October 30, Bayer admitted that in the past three months, the number of U.S plaintiffs accused of cancer caused by Roundup glyphosate doubled to 42700, a figure it attributed to advertising by injury claims lawyers Although both Monsanto and Bayer denied the charges and strongly challenged them in court, in three cases, the jury sided with the plaintiff and found that the use of Roundup led to non Hodgkin's lymphoma Here is the ranking details of Gen in 2019 and recent years: reference source: TOP10 pharma companies of 2019
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.